|
| Press Releases |
|
 |
|
| Tuesday, August 6, 2024 |
|
|
康哲藥業：甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批 |
| 康哲藥業控股有限公司（“本公司”，連同其附屬公司統稱為“本集團”或“康哲藥業”）欣然宣佈，甲氨蝶呤注射液（“產品”）增加適應症的上市許可申請（NDA）已於2024年7月30日獲得國家藥品監督管理局（NMPA）批准。 more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 16, 2024 |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
| Tuesday, June 25, 2024 |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
| Tuesday, June 18, 2024 |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
| Tuesday, April 23, 2024 |
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Jeff Cooperstein Named Kadena Business Development Lead, Digital Assets
Aug 6, 2024 23:00 HKT/SGT
|
|
|
Food Expo Kicks Off Next Week with Four Thematic Days to Explore Infinite Lifestyle Possibilities
Aug 6, 2024 21:06: JST
|
|
|
GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisation
Aug 6, 2024 20:09 HKT/SGT
|
|
|
Food Expo Kicks Off Next Week with Four Thematic Days to Explore Infinite Lifestyle Possibilities
Aug 6, 2024 20:06 HKT/SGT
|
|
|
DENSO Signs Manufacturing License Agreement for SOEC Cell Stacks with Ceres Power Holdings of the UK
Aug 6, 2024 20:21 JST
|
|
|
U.S. Polo Assn. Moves Up Two Spots in License Global's Top 25 'Top Global Licensors'
Aug 6, 2024 19:00 HKT/SGT
|
|
|
康哲藥業：甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批
Aug 6, 2024 17:37 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Achieves Strong YoY Increases in Order Intake, Revenue, and Profit in Q1 FY2024
Aug 6, 2024 15:25 JST
|
|
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Aug 6, 2024 13:15 JST
|
|
|
Research Analysis: Fosun is on Track for Valuation Recovery
Aug 6, 2024 11:42 HKT/SGT
|
|
|
深度研报：四大逻辑支撑复星国际估值修复
Aug 6, 2024 11:35 HKT/SGT
|
|
|
深度研報：四大邏輯支撐復星國際估值修復
Aug 6, 2024 11:25 HKT/SGT
|
|
|
Championing Tomorrow's Zero-Incident Strategy: Pioneering Safety, Sustainability, and Success in Workplace Health
Aug 6, 2024 11:07 HKT/SGT
|
|
|
周杰倫官方IP周同學亮相東京塔 巨星傳奇在下一盤什麼棋？
Aug 6, 2024 10:03 HKT/SGT
|
|
|
周杰伦官方IP周同学亮相东京塔 巨星传奇在下一盘什么棋？
Aug 6, 2024 10:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
